KYMR in the 13F filings
Kymera Therapeutics Inc · CUSIP 501575104
- Quarter end
- 31 Dec 2023
- the date the book describes
- Filed
- 16 Feb 2024
- latest of these filings; the earliest 14 Feb 2024
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q3 2023 and Q4 2023; 1 listed it in both
- Shares listed
- 5,874,096
- combined, among listed positions
- Reported value
- $150m
- combined, at the quarter end
Among the 93 comparable managers: 2 buyers (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing KYMR in Q4 2023
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| T. Rowe Price Associates Inc | 5,335,712 | $136m | under 0.1% | Added | n.a. | 16 Feb 2024 (the filing on sec.gov) |
| Schonfeld Strategic Advisors LLC | 437,633 | $11m | 0.07% | New | new | 14 Feb 2024 (the filing on sec.gov) |
| Woodline Partners LP | 100,751 | $2.6m | under 0.1% | Trimmed | -2,438 | 14 Feb 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Schonfeld Strategic Advisors LLCnew position · 437,633 shares now+437,633
Reductions
- Woodline Partners LPexisting position · 100,751 shares now-2,438
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2020 | 2 | $8.3m | n.a. | n.a. |
| Q4 2020 | 1 | $11m | n.a. | n.a. |
| Q2 2021 | 1 | $1.8m | n.a. | n.a. |
| Q3 2021 | 1 | $7.6m | n.a. | n.a. |
| Q4 2021 | 1 | $171m | n.a. | n.a. |
| Q1 2022 | 2 | $30m | n.a. | n.a. |
| Q2 2022 | 1 | $2.0m | n.a. | n.a. |
| Q3 2022 | 1 | $2.2m | n.a. | n.a. |
| Q4 2022 | 3 | $226m | n.a. | n.a. |
| Q1 2023 | 3 | $268m | n.a. | n.a. |
| Q2 2023 | 1 | $2.5m | n.a. | n.a. |
| Q3 2023 | 1 | $1.4m | n.a. | n.a. |
| Q4 2023 | 3 | $150m | 2 | 1 |
| Q1 2024 | 6 | $496m | 4 | 2 |
| Q2 2024 | 4 | $343m | 3 | 1 |
| Q3 2024 | 5 | $582m | 3 | 2 |
| Q4 2024 | 6 | $536m | 5 | 1 |
| Q1 2025 | 4 | $372m | 2 | 3 |
| Q2 2025 | 5 | $615m | 3 | 2 |
| Q3 2025 | 6 | $737m | 2 | 3 |
| Q4 2025 | 7 | $1.7bn | 15 | 12 |
| Q1 2026 | 8 | $2.1bn | 12 | 15 |
| Q2 2026 | 8 | $3.0bn | 12 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
KYMR and GILD →KYMR and AMGN →KYMR and ARGX →Choose a stock to compare with KYMR →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own KYMR, latest filings →Back to the 13F Explorer →